Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 22.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,133 shares of the biotechnology company’s stock after selling 3,549 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Axon Enterprise were worth $3,134,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP increased its position in shares of Axon Enterprise by 184.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after purchasing an additional 451,350 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at approximately $32,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in Axon Enterprise by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock valued at $29,320,000 after purchasing an additional 495 shares during the period. International Assets Investment Management LLC acquired a new position in Axon Enterprise during the fourth quarter worth $39,907,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Axon Enterprise by 11.5% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 63,778 shares of the biotechnology company’s stock worth $12,691,000 after buying an additional 6,585 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. Morgan Stanley boosted their price objective on Axon Enterprise from $250.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Robert W. Baird boosted their price target on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 22nd. The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Barclays lifted their price objective on shares of Axon Enterprise from $296.00 to $308.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, StockNews.com lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $312.64.

Axon Enterprise Stock Down 0.2 %

Shares of Axon Enterprise stock opened at $299.82 on Thursday. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The company has a 50 day moving average of $299.84 and a 200 day moving average of $257.02. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $22.62 billion, a P/E ratio of 130.36 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.29. The business had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. As a group, research analysts forecast that Axon Enterprise, Inc. will post 2.43 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.